You will be shown inclusion or exclusion criteria for a clinical trial. Given these criteria, your task is to extract all unique entities of the following types: ["Observation", "Condition", "Procedure", "Drug", "Temporal", "Multiplier", "Qualifier", "Negation", "ReferencePoint", "Scope", "Value", "Mood", "Device", "Visit", "Measurement", "Person"].

Please return the output as a JSON object of the format: {"Condition" : ["breast cancer", ...], "Device" : ["ports", ...], "Drug" : ["Atenolol", ...], "Measurement" : ["blood pressure", ...], "Mood" : ["suspected", ...], "Multiplier" : ["more than two", ...], "Negation" : ["no", ...], "Observation" : ["history", ...], "Person" : ["male", ...], "Procedure" : ["surgery", ...], "Qualifier" : ["severe", ...], "ReferencePoint" : ["enrollment", ...], "Scope" : ["infection", ...], "Temporal" : ["one day", ...], "Value" : ["50%", ...], "Visit" : ["ICU", ...]}. The keys should be entity types and values should be lists of extracted entities belonging to the corresponding type. If you cannot find entities belonging to a specific type, the value should be [].

Only output the JSON object and do not include any additional text.

Abstract:

Antiretroviral naive
Taking Kaletra containing regimen with suppressed viral load.
Taking an NNRTI or integrase containing regimen without prior history of use of PI for more than 2 weeks
Taking an NNRTI or integrase containing regimen with prior exposure to PI greater than 2 weeks. It must be clearly stated in the source document that PI was switched to another agent for convenience.
Taking another PI containing regimens with suppressed viral load. It must be clearly stated in source document that if another PI was used for greater than 2 weeks the regimen was switched to another agent for convenience. Subjects with prior history of PI use may be enrolled, if there is a genotype showing no resistance to Kaletra Other Inclusion criteria
Be at least 18 years of age and able to give informed consent.
Diagnosed with TB by criteria per Brazilian Ministry of Health
Have a good clinical response to TB.
Tolerating tuberculosis therapy containing rifampin for the 2 weeks prior to screening,except for persons taking protease inhibitors at time of diagnosis of TB.,. Subjects taking protease inhibitors will be screened and initiate visit 1 within 3 days of starting TB medication
HIV positive with documentation present in source document.
Have a CD4 cell count greater than 50 cells/mm3if not taking ART. Persons with cd4 < 50 may be enrolled, if it is felt that in the best interest of the patient, that enrollment in the study will allow for quicker initiation of antiretroviral therapy than referral to another treatment center.
{"Condition": ["tuberculosis", "HIV positive", "good clinical response", "TB", "naive"], "Device": [], "Drug": ["rifampin", "Kaletra", "PI", "protease inhibitors", "NNRTI", "Antiretroviral", "integrase"], "Measurement": ["HIV", "viral load", "CD4 cell count"], "Mood": [], "Multiplier": [], "Negation": ["except", "not", "without"], "Observation": [], "Person": ["age"], "Procedure": ["regimens", "tuberculosis therapy", "ART", "regimen"], "Qualifier": ["criteria per Brazilian Ministry of Health"], "ReferencePoint": ["time of diagnosis of TB", "screening"], "Scope": ["NNRTI or integrase", "not taking ART"], "Temporal": ["at time of diagnosis of TB", "prior", "for the 2 weeks prior to screening", "greater than 2 weeks"], "Value": ["at least 18 years", "greater than 50 cells/mm3", "positive", "suppressed", "for more than 2 weeks"], "Visit": []}